NI201000177A - Conjugados de factor ix con vidas medias prolongadas. - Google Patents
Conjugados de factor ix con vidas medias prolongadas.Info
- Publication number
- NI201000177A NI201000177A NI201000177A NI201000177A NI201000177A NI 201000177 A NI201000177 A NI 201000177A NI 201000177 A NI201000177 A NI 201000177A NI 201000177 A NI201000177 A NI 201000177A NI 201000177 A NI201000177 A NI 201000177A
- Authority
- NI
- Nicaragua
- Prior art keywords
- factor
- conjugates
- lives
- extended half
- contamination
- Prior art date
Links
- 229960004222 factor ix Drugs 0.000 title abstract 4
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 3
- 108010076282 Factor IX Proteins 0.000 abstract 3
- 108010048049 Factor IXa Proteins 0.000 abstract 1
- 229920000249 biocompatible polymer Polymers 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4754408P | 2008-04-24 | 2008-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201000177A true NI201000177A (es) | 2011-08-29 |
Family
ID=41171051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201000177A NI201000177A (es) | 2008-04-24 | 2010-10-22 | Conjugados de factor ix con vidas medias prolongadas. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20110183906A1 (enExample) |
| EP (1) | EP2280734B1 (enExample) |
| JP (1) | JP2011519833A (enExample) |
| KR (1) | KR20110016440A (enExample) |
| CN (1) | CN102046205A (enExample) |
| AU (1) | AU2009239641B2 (enExample) |
| BR (1) | BRPI0911350A2 (enExample) |
| CA (1) | CA2722169A1 (enExample) |
| CO (1) | CO6300965A2 (enExample) |
| CR (1) | CR11763A (enExample) |
| DK (1) | DK2280734T3 (enExample) |
| EC (1) | ECSP10010632A (enExample) |
| ES (1) | ES2466340T3 (enExample) |
| IL (1) | IL208908A0 (enExample) |
| MX (1) | MX2010011672A (enExample) |
| MY (1) | MY158228A (enExample) |
| NI (1) | NI201000177A (enExample) |
| NZ (1) | NZ588854A (enExample) |
| RU (1) | RU2496521C2 (enExample) |
| UA (1) | UA101497C2 (enExample) |
| WO (1) | WO2009130602A2 (enExample) |
| ZA (1) | ZA201007559B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2101821T3 (da) | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo |
| BR112012001814A8 (pt) | 2009-07-27 | 2018-02-06 | Baxalta GmbH | Conjugados de proteína de coagulação sanguínea |
| EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| EP2467166A2 (en) * | 2009-08-20 | 2012-06-27 | CSL Behring GmbH | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| MX375112B (es) * | 2010-07-09 | 2025-03-06 | Biogen Hemophilia Inc | Polipéptidos de factor ix y métodos para usarlos. |
| ES2800983T3 (es) | 2010-12-22 | 2021-01-07 | Baxalta GmbH | Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína |
| EP3412314A1 (en) * | 2011-05-27 | 2018-12-12 | Baxalta GmbH | Therapeutic proteins conjugated to polysialic acid and methods of preparing same |
| HK1200695A1 (en) * | 2012-04-16 | 2015-08-14 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
| BR112014031613A2 (pt) * | 2012-06-19 | 2017-07-25 | Polytherics Ltd | processo para preparação de conjugados de anticorpos e conjugados de anticorpos |
| WO2014052490A1 (en) | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
| SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| AR099340A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados del factor de coagulación ix |
| EA202092926A3 (ru) | 2014-03-24 | 2021-10-29 | Биовератив Терапьютикс Инк. | Лиофилизированные составы, содержащие фактор ix |
| GB2564389A (en) | 2017-07-04 | 2019-01-16 | Green Running Ltd | A system and method for utility management |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171569A (en) | 1985-03-15 | 1992-12-15 | National Research Development Corporation | Factor IX preparations uncontaminated by plasma components or pox virus |
| US5268275A (en) | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| WO2001058935A2 (en) * | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| KR101031206B1 (ko) * | 2002-12-31 | 2011-04-27 | 넥타르 테라퓨틱스 | 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트 |
| ATE444984T1 (de) * | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| US7910661B2 (en) * | 2003-01-06 | 2011-03-22 | Nektar Therapeutics | Thiol-selective water-soluble polymer derivatives |
| GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| ATE455174T1 (de) | 2003-09-23 | 2010-01-15 | Univ North Carolina | Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein |
| JP4855074B2 (ja) * | 2003-09-30 | 2012-01-18 | 一般財団法人化学及血清療法研究所 | 高純度血液凝固ｉｘ因子調製物およびその精製方法 |
| EP2272951B1 (en) | 2003-10-14 | 2014-07-23 | Baxter International Inc. | Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| JP2008505119A (ja) * | 2004-06-30 | 2008-02-21 | ネクター セラピューティクス アラバマ，コーポレイション | 高分子−第ｉｘ因子部分の抱合体 |
| WO2006063292A1 (en) | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
| KR101310532B1 (ko) | 2005-02-28 | 2013-09-23 | 박스터 헬쓰케어 에스에이 | 비타민 ｋ 의존성 단백질 발현의 개선을 위한 비타민 ｋ에폭사이드 환원효소 소단위 １의 재조합 동시발현 |
| CA2601574C (en) | 2005-03-15 | 2014-12-02 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
| US20080255026A1 (en) * | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
| WO2007126808A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc | Pegylated factor viii |
| AU2007253264A1 (en) * | 2006-05-24 | 2007-11-29 | Novo Nordisk Health Care Ag | Factor IX analogues having prolonged in vivo half life |
| JP5737821B2 (ja) * | 2006-08-17 | 2015-06-17 | 一夫 大橋 | 血友病ｂ治療剤及びその製造方法 |
-
2009
- 2009-04-24 KR KR1020107026368A patent/KR20110016440A/ko not_active Ceased
- 2009-04-24 CA CA2722169A patent/CA2722169A1/en not_active Abandoned
- 2009-04-24 EP EP09734192.9A patent/EP2280734B1/en not_active Not-in-force
- 2009-04-24 AU AU2009239641A patent/AU2009239641B2/en not_active Ceased
- 2009-04-24 BR BRPI0911350A patent/BRPI0911350A2/pt not_active IP Right Cessation
- 2009-04-24 UA UAA201013989A patent/UA101497C2/ru unknown
- 2009-04-24 RU RU2010147813/15A patent/RU2496521C2/ru not_active IP Right Cessation
- 2009-04-24 JP JP2011505616A patent/JP2011519833A/ja active Pending
- 2009-04-24 MX MX2010011672A patent/MX2010011672A/es active IP Right Grant
- 2009-04-24 ES ES09734192.9T patent/ES2466340T3/es active Active
- 2009-04-24 CN CN200980119877XA patent/CN102046205A/zh active Pending
- 2009-04-24 NZ NZ588854A patent/NZ588854A/en not_active IP Right Cessation
- 2009-04-24 US US12/989,555 patent/US20110183906A1/en not_active Abandoned
- 2009-04-24 MY MYPI2010004993A patent/MY158228A/en unknown
- 2009-04-24 WO PCT/IB2009/005763 patent/WO2009130602A2/en not_active Ceased
- 2009-04-24 DK DK09734192.9T patent/DK2280734T3/da active
-
2010
- 2010-10-22 NI NI201000177A patent/NI201000177A/es unknown
- 2010-10-22 ZA ZA2010/07559A patent/ZA201007559B/en unknown
- 2010-10-24 IL IL208908A patent/IL208908A0/en unknown
- 2010-10-27 CR CR11763A patent/CR11763A/es not_active Application Discontinuation
- 2010-11-24 CO CO10147494A patent/CO6300965A2/es not_active Application Discontinuation
- 2010-11-24 EC EC2010010632A patent/ECSP10010632A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011519833A (ja) | 2011-07-14 |
| MY158228A (en) | 2016-09-15 |
| WO2009130602A2 (en) | 2009-10-29 |
| WO2009130602A3 (en) | 2010-02-11 |
| EP2280734B1 (en) | 2014-02-26 |
| RU2010147813A (ru) | 2012-05-27 |
| UA101497C2 (ru) | 2013-04-10 |
| CO6300965A2 (es) | 2011-07-21 |
| BRPI0911350A2 (pt) | 2017-12-05 |
| AU2009239641A1 (en) | 2009-10-29 |
| RU2496521C2 (ru) | 2013-10-27 |
| US20110183906A1 (en) | 2011-07-28 |
| DK2280734T3 (da) | 2014-05-26 |
| ES2466340T3 (es) | 2014-06-10 |
| AU2009239641B2 (en) | 2013-11-07 |
| WO2009130602A9 (en) | 2010-04-22 |
| EP2280734A2 (en) | 2011-02-09 |
| CA2722169A1 (en) | 2009-10-29 |
| HK1151986A1 (en) | 2012-02-17 |
| KR20110016440A (ko) | 2011-02-17 |
| MX2010011672A (es) | 2011-03-02 |
| NZ588854A (en) | 2011-12-22 |
| IL208908A0 (en) | 2011-01-31 |
| ECSP10010632A (es) | 2011-02-28 |
| CR11763A (es) | 2011-04-26 |
| CN102046205A (zh) | 2011-05-04 |
| ZA201007559B (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010632A (es) | Conjugados del factor ix con vidas medias extendidas | |
| CY1123675T1 (el) | Πολυαιθυλενογλυκολιωμενου φαρμακου-συνδετες για βελτιωμενες φαρμακοκινητικες προϊοντος συζευξης προσδετη-φαρμακου | |
| CU20110109A7 (es) | Nueva composición a base de ácido gamma-hidroxibutírico | |
| CY1121225T1 (el) | Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις | |
| MX2020002666A (es) | Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato. | |
| CY1115844T1 (el) | Μακροκυκλικοι αναστολεις της πρωτεασης σερινης της ηπατιτιδας c | |
| BRPI0920914A8 (pt) | Perácidos alfa-ceto e métodos para produzir e usar os mesmos. | |
| CR20110002S (es) | Barra de chocolate | |
| CY1116803T1 (el) | Φαρμακευτικος συνδυασμος για χρηση στον γλυκαιμικο ελεγχο σε ασθενεις με διαβητη τυπου 2 | |
| PL1909755T3 (pl) | Nanotechnologia cyklodekstryn do dostarczania leku do oczu | |
| MX374694B (es) | USO DE 1-CLORO-4-(ß-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO EN COMBINACIÓN CON INSULINA PARA REDUCIR LA DOSIS DE INSULINA Y PARA MEJORAR EL CONTROL GLUCÉMICO EN PACIENTES CON DIABETES MELLITUS. | |
| MA32703B1 (fr) | Combinaison d'une insuline et d'un agoniste de glp 1 | |
| BR112013007362A2 (pt) | composição farmacêutica | |
| CR20140334A (es) | Forma galénica divisible que permite una liberación modificada del principio activo | |
| UY31785A1 (es) | Sistema polimerico de lagrimas artificiales | |
| CL2008002809A1 (es) | Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros. | |
| CL2015003580A1 (es) | Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima. | |
| MX341778B (es) | Goma de mascar natural incluyendo materiales de celulosa. | |
| MX2011011858A (es) | Composiciones borinicas. | |
| BR112015009603A2 (pt) | novos derivados de pirazina | |
| BR112013025694A2 (pt) | degradação intensificada de celulose | |
| RU2011135537A (ru) | Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов | |
| ATE535494T1 (de) | Wasserstoffspeichermaterial | |
| SA515360200B1 (ar) | محاكيات عامل نمو خلية كبدية كعوامل علاجية | |
| CL2014002430A1 (es) | Uso del compuesto r-p88 (metabolito activo de iloperidona en su forma enantiomerica r) para tratar una enfermedad psiquiatrica tal como esquizofrenia, trastorno bipolar, depresion, autismo, entre otras, cuando se administra una vez al dia; y composicion farmaceutica que comprende el compuesto r-p88. |